Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Akebia Therapeutics and Compass Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
Akebia Therapeutics currently has a consensus target price of $3.90, indicating a potential upside of 722.44%. Compass Therapeutics has a consensus target price of $9.99, indicating a potential upside of 1,191.25%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Akebia Therapeutics.
Risk and Volatility
Akebia Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Institutional & Insider Ownership
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Akebia Therapeutics and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -22.60% | -156.59% | -11.53% |
| Compass Therapeutics | N/A | -49.93% | -43.76% |
Earnings & Valuation
This table compares Akebia Therapeutics and Compass Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $236.20 million | 0.56 | -$5.34 million | ($0.16) | -2.96 |
| Compass Therapeutics | $850,000.00 | 163.95 | -$66.49 million | ($0.47) | -1.65 |
Akebia Therapeutics has higher revenue and earnings than Compass Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Compass Therapeutics beats Akebia Therapeutics on 11 of the 15 factors compared between the two stocks.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
